Research Analysts Issue Forecasts for RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Equities researchers at William Blair decreased their FY2025 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report released on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings of ($5.36) per share for the year, down from their previous forecast of ($3.48). William Blair currently has a "Outperform" rating and a $65.00 target price on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. William Blair also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.17) EPS, Q1 2026 earnings at ($1.33) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at $0.46 EPS and FY2026 earnings at ($0.85) EPS.

RARE has been the topic of several other research reports. Wells Fargo & Company dropped their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research note on Thursday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Guggenheim reaffirmed a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Finally, Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $83.64.

Ultragenyx Pharmaceutical Stock Down 4.0%

Shares of NASDAQ RARE traded down $1.10 during trading on Wednesday, reaching $26.31. 3,904,088 shares of the company traded hands, compared to its average volume of 976,201. The firm has a 50 day simple moving average of $35.65 and a 200-day simple moving average of $38.25. Ultragenyx Pharmaceutical has a 52-week low of $26.00 and a 52-week high of $60.37. The stock has a market capitalization of $2.49 billion, a PE ratio of -4.47 and a beta of 0.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The firm had revenue of $139.29 million for the quarter, compared to analysts' expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The company's quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.03) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company's stock worth $3,284,000 after buying an additional 268 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the period. Xponance Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 2.8% during the 1st quarter. Xponance Inc. now owns 12,552 shares of the biopharmaceutical company's stock worth $455,000 after buying an additional 347 shares during the period. BOKF NA grew its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after purchasing an additional 382 shares during the last quarter. Finally, Oak Ridge Investments LLC grew its position in Ultragenyx Pharmaceutical by 2.3% during the 1st quarter. Oak Ridge Investments LLC now owns 17,757 shares of the biopharmaceutical company's stock worth $643,000 after acquiring an additional 395 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 3,167 shares of company stock valued at $118,824 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.